FLT3 and acute myeloid leukemia: The poor efficacy of FLT3-ITD inhibitors for FLT3-ITD+ AML [22,23] underscores the need to investigate the mechanism responsible for the drug-resistant phenotype of FLT3-ITD+ AML.